Hemolytic-Uremic Syndrome
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The genetic workup found a complement factor H gene variant which has been associated with atypical HUS.
|
30560448 |
2019 |
Hemolytic-Uremic Syndrome
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study aimed to evaluate practice patterns during prodromal phase of hemolytic uremic syndrome related to Shiga toxin-producing Escherichia coli (STEC-HUS).
|
31290797 |
2019 |
Hemolytic-Uremic Syndrome
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Liver lesions of hemolytic uremic syndrome due to Shiga-toxin-producing Escherichia coli (STEC-HUS) are uncommon.
|
30963282 |
2019 |
Hemolytic-Uremic Syndrome
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Genetic testing of the complement alternative pathway revealed a rare - potentially pathogenic - variant of factor H. This constitutes a possible factor of susceptibility for atypical HUS, suggesting that E.coli infection may be the trigger.
|
31064333 |
2019 |
Hemolytic-Uremic Syndrome
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A 6-year-old boy with complement factor H (CFH) and factor B (CFB) mutations and a history of bloody diarrhoea and PCR positivity for Shiga toxin was initially diagnosed as STEC+HUS.
|
31242818 |
2019 |
Hemolytic-Uremic Syndrome
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Thrombocytopenia is a hallmark of postdiarrhoeal haemolytic uraemic syndrome (D+ HUS), although it can be transient and therefore undetected.
|
28946963 |
2018 |
Hemolytic-Uremic Syndrome
|
0.400 |
Biomarker
|
disease |
BEFREE |
Deficiency of complement factor H-related proteins and autoantibody-positive hemolytic uremic syndrome in an infant with combined partial deficiencies and autoantibodies to complement factor H and ADAMTS13.
|
30524124 |
2018 |
Hemolytic-Uremic Syndrome
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In children, Shiga toxin-associated haemolytic uraemic syndrome due to infection with Escherichia coli (STEC-HUS) is the commonest cause of TMA, and is managed supportively.
|
29582550 |
2018 |
Hemolytic-Uremic Syndrome
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Postdiarrheal hemolytic-uremic syndrome (D+HUS) following Shiga toxin-producing Escherichia coli (STEC) infection is a serious condition lacking specific treatment.
|
29216383 |
2018 |
Hemolytic-Uremic Syndrome
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Shiga-toxin producing O157:H7 Entero Haemorrhagic E. coli [STEC/EHEC] are the most common cause of Haemolytic Uraemic Syndrome [HUS] related to infectious haemorrhagic colitis.
|
29420567 |
2018 |
Hemolytic-Uremic Syndrome
|
0.400 |
Biomarker
|
disease |
BEFREE |
Endothelial injury with consecutive microangiopathy and endothelial dysfunction plays a central role in the pathogenesis of the postenteropathic hemolytic uremic syndrome (D + HUS).
|
29513070 |
2018 |
Hemolytic-Uremic Syndrome
|
0.400 |
Biomarker
|
disease |
BEFREE |
The clinical and laboratory features of Chinese Han anti-factor H autoantibody-associated hemolytic uremic syndrome.
|
28035470 |
2017 |
Hemolytic-Uremic Syndrome
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Murine systemic thrombophilia and hemolytic uremic syndrome from a factor H point mutation.
|
28057640 |
2017 |
Hemolytic-Uremic Syndrome
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To our knowledge, this is the first reported case of a child with DEAP-HUS treated with the combination of eculizumab and immunosuppression as first-line therapy avoiding any HUS- or therapy-related complications and resulting in prompt clinical recovery.
|
28220235 |
2017 |
Hemolytic-Uremic Syndrome
|
0.400 |
Biomarker
|
disease |
BEFREE |
Hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli (STEC HUS) is a worldwide endemic problem, and its pathophysiology is not fully elucidated.
|
27378476 |
2016 |
Hemolytic-Uremic Syndrome
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We report a case of STEC-HUS with a quantitative CFH defect caused by a mutation of the CFH gene.
|
26399238 |
2016 |
Hemolytic-Uremic Syndrome
|
0.400 |
Biomarker
|
disease |
BEFREE |
The clinical spectrum of hemolytic uremic syndrome secondary to complement factor H autoantibodies.
|
24131678 |
2015 |
Hemolytic-Uremic Syndrome
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The rarer atypical form of HUS is often associated with complement dysregulation, owing to the inherited deficiency or dysfunction of factor H or other complement proteins.
|
26386489 |
2015 |
Hemolytic-Uremic Syndrome
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, multiple interactions of key complement inhibitors FH, FHR-1 and FHL-1 with Stx2 corroborate our hypothesis of a direct role of complement in EHEC-associated HUS.
|
24317278 |
2014 |
Hemolytic-Uremic Syndrome
|
0.400 |
Biomarker
|
disease |
BEFREE |
In order to explore this we studied a multicenter cohort of 138 Indian children with anti-complement factor H antibody associated HUS, constituting 56% of patients with HUS.
|
24088957 |
2014 |
Hemolytic-Uremic Syndrome
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
E. coli O104:H4 outbreak isolates from 170 patients (128 with hemolytic uremic syndrome [HUS] and 42 with diarrhea without HUS) were tested for pAA using polymerase chain reaction and plasmid profiling. pAA-harboring bacteria in stool samples were quantified using colony blot hybridization, and adherence to HCT-8 cells was determined.
|
23805269 |
2013 |
Hemolytic-Uremic Syndrome
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A 26-year-old woman with a homozygous mutation in complement factor H developed a relapse of atypical HUS at 17 weeks of gestation in her first pregnancy.
|
23884270 |
2013 |
Hemolytic-Uremic Syndrome
|
0.400 |
Biomarker
|
disease |
BEFREE |
Complement mediated HUS (aHUS) has a worse prognosis compared with shiga toxin mediated HUS, often resulting in end stage renal disease.
|
23399570 |
2013 |
Hemolytic-Uremic Syndrome
|
0.400 |
Biomarker
|
disease |
BEFREE |
Clinical manifestations arising from CFH gene (CFH) abnormalities include hemolytic uremic syndrome and membranoproliferative glomerulonephritis.
|
22790979 |
2012 |
Hemolytic-Uremic Syndrome
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thus, exogenous CFHR1 provided during plasma exchange therapy may neutralize anti-factor H autoantibodies and help in the treatment of autoimmune atypical HUS.
|
21677636 |
2011 |